Speaker Profile
M.D., Director, Institute for Aging Research; President, Academy for Health and Lifespan Research., Albert Einstein College of Medicine
Biography
Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted. At Albert Einstein College of Medicine, he is a professor in the departments of Medicine and Genetics, the director of the Institute for Aging Research, and the director of the Einstein-National Institutes of Health (NIH) Nathan Shock Center of Excellence in the Basic Biology of Aging, and the author of more than 350 papers. He made seminal discoveries in extending the health and lifespan of animals and discovering pathways for exceptional longevity in humans. He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Dr. Barzilai to prove that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging. Dr. Barzilai is a co- founder and the President of A HLS. He is also on the board of directors of the American Federation for Aging Research, where he co-leads its biomarker effort (FAST), TAME, and Super Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) and serves on the Healthy Longevity Medicine Society council. He authored Age Later: Health Span, Life Span, and the New Science of Longevity.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Nir Barzilai, Albert Einstein & Mike Snyder, Stanford
PMWC Award Ceremony
• Alexander (Zan) Fleming, Hevolution Foundation (Pioneer)
• Daniel Drucker, Sinai Health (Pioneer)
• Andrea Maier, NUS Yong Loo Lin School of Medicine (Luminary)
Featured Speakers
• Nir Barzilai, Albert Einstein
• Mike Snyder, Stanford
• Andrea Maier, NUS Yong Loo Lin School of Medicine
• Sara Espinoza, Cedars-Sinai
• Brian Kennedy, Buck Institute
• John Newman, Buck Institute / UCSF
• Marco Quarta, Rubedo Life Sciences
• Maria Dermit, Novo Nordisk
• Alan Shuldiner, Regeneron
• David Furman, Stanford
• Steve Horvath, UCLA
• Daniel Belsky, Columbia
• Ahmed Metwally, Google
• Lee Hood, Phenome Health / ISB
• George Slavich, UCLA
Targeting Aging Biology
What is actually druggable today, and what remains wishful thinking.
From Metabolism to Longevity: GLP-1 and Beyond
Incretins reshaping cardiometabolic prevention and healthy aging.
Which Aging Measures Matter?
Biological-age measures and biomarkers that can change clinical decisions.
Wearables & Digital Biomarkers at Scale
Continuous phenotyping and longitudinal signals in real-world aging.
Clinical Translation
Trials, endpoints, regulation, and the hard road to credible longevity medicine.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
